摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(2-氨基嘌呤-9-基)甲氧基]丙烷-1,3-二醇 | 89419-23-8

中文名称
2-[(2-氨基嘌呤-9-基)甲氧基]丙烷-1,3-二醇
中文别名
——
英文名称
9-<<2-hydroxy-1-(hydroxymethyl)ethoxy>methyl>-2-aminopurine
英文别名
2-amino-9-[(2-hydroxy-1-hydroxymethylethoxy)methyl]-9H-purine;9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-2-aminopurine;1,3-Propanediol, 2-[(2-amino-9H-purin-9-yl)methoxy]-;2-[(2-aminopurin-9-yl)methoxy]propane-1,3-diol
2-[(2-氨基嘌呤-9-基)甲氧基]丙烷-1,3-二醇化学式
CAS
89419-23-8
化学式
C9H13N5O3
mdl
——
分子量
239.234
InChiKey
WVDCJUSYASXINB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    612.6±65.0 °C(Predicted)
  • 密度:
    1.66±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.7
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    119
  • 氢给体数:
    3
  • 氢受体数:
    7

SDS

SDS:84dd9a96571c96ce4f4d53210ed7d65f
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    与9-[(1,3-二羟基-2-丙氧基)甲基]鸟嘌呤有关的2'-脱氧核苷的无环类似物作为潜在的抗病毒药。
    摘要:
    合成了一系列与9-[(1,3-二羟基-2-丙氧基)甲基]鸟嘌呤(DHPG,1)结构相关的2'-脱氧核苷的无环类似物,并评估了其对1型单纯疱疹病毒的抗病毒活性。 (F株)。另外,检查了这些类似物充当病毒指定的胸苷激酶底物的能力。该激酶的磷酸化对于抗病毒活性至关重要。尽管无环4-氧代嘧啶核苷是该激酶的底物,但它们没有抗病毒活性。在嘌呤系列中,大多数结构上与DHPG类似的类似物确实表现出明显较低的抗病毒活性,这表明即使嘌呤取代基进行很小的修饰也会大大降低抗病毒能力。活性最高的试剂2,6-二氨基嘌呤27 仅被病毒激酶磷酸化差;因此,其活性最有可能是由于事先进行了酶促脱氨作用而生成了DHPG。在小鼠脑炎模型中对27种药物的评估显示,其效力几乎与DHPG(1)相同。
    DOI:
    10.1021/jm00381a015
点击查看最新优质反应信息

文献信息

  • Synthesis of a purine acyclonucleoside series having pronounced antiviral activity. The glyceropurines
    作者:Kelvin K. Ogilvie、Nghe Nguyen-Ba、Michael F. Gillen、Bruno K. Radatus、Ukken O. Cheriyan、H. Rizk Hanna、Kendall O. Smith、Karen S. Galloway
    DOI:10.1139/v84-039
    日期:1984.2.1

    The synthesis of a series of purine analogues of the acyclonucleoside compound A* (A-Star, 1) is described. Compounds in this series have been shown to have pronounced activity against herpesviruses. These compounds have been designated "the glycerosides". The glyceropurines are described in this report. Nucleotides have been constructed containing glyceroadenine (A*, compound 1). These nucleotides are resistant to degradation by phosphodiesterases. The compound A* is both a poor substrate and a poor inhibitor of adenosine deaminase.

    描述了一系列嘌呤类似物A*(A-Star,1)的无环核苷化合物的合成。该系列化合物已被证明对疱疹病毒具有显著的活性。这些化合物被命名为“甘油苷”。本报告描述了甘油嘌呤。已构建含有甘油腺嘌呤(A*,化合物1)的核苷酸,这些核苷酸对磷酸二酯酶的降解具有抵抗性。化合物A*既是腺苷脱氨酶的劣质底物,也是劣质抑制剂。
  • Method for using purine derivatives
    申请人:Burroughs Wellcome Co.
    公开号:US04745119A1
    公开(公告)日:1988-05-17
    The novel 2-aminopurine derivatives disclosed herein which have a hydrogen atom in the 6-position and an acyclic chain ##STR1## in the 9-position [wherein X=O or S, Y=H or CH.sub.2 OR and R=H or ##STR2## wherein R.degree.=H, C.sub.1-16 alkyl (preferably C.sub.1-6 alkyl), optionally substituted aralkyl or optionally substituted aryl, provided at least one R is ##STR3## are converted in vivo by the action of xanthine oxidase/dehydrogenase or aldehyde oxidase and esterase enzymes into the corresponding 6-hydroxy compounds wherein R=H, which are potent antiviral compounds.
    本文披露的新型2-氨基嘌呤衍生物,在6-位具有氢原子,在9-位具有一个无环链##STR1## [其中X=O或S,Y=H或CH.sub.2或R,R=H或##STR2##其中R.degree.=H,C.sub.1-16烷基(优选C.sub.1-6烷基),可选取代的芳基烷基或可选取代的芳基,至少一个R为##STR3##],在体内经过黄嘌呤氧化酶/脱氢酶或醛脱氢酶和酯酶酶作用转化为相应的6-羟基化合物,其中R=H,这些化合物是有效的抗病毒化合物。
  • Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent
    申请人:SYNTEX (U.S.A.) INC.
    公开号:EP0085424A2
    公开(公告)日:1983-08-10
    Compounds useful as antiviral agents are defined by the following formula: and the acid addition salts, preferably the pharmaceutically acceptable acid addition salt thereof, wherein R1 is hydrogen or -C(O)R7 wherein R7 is hydrogen, alkyl of one to nineteen carbon atoms, hydroxyalkyl of one to eight carbon atoms, alkoxyalkyl of two to nine carbon atoms, alkenyl of two to nineteen carbon atoms, phenyl, 1- adamantyl, 2-carboxyethyl or carboxymethyl and the pharmaceutically acceptable alkali metal salts thereof; R2 is -C(O)R7 wherein R7 is as defined above; R3 is hydrogen, halo, thio, lower alkylthio of one to six carbon atoms, azido, NR9R10 wherein R9 and R10 are independently hydrogen or lower alkyl of one to six carbon atoms or -NHC(O)R8 wherein R8 is hydrogen, alkyl of one to nineteen carbon atoms or 1-adamantyl; and (a) R6 is hydrogen, halo, lower alkoxy of one to six carbon atoms, azido, thio, lower alkythio of one to six carbon atoms, -NR9R10 wherein R9 and R10 are as defined above or -NHC(O)R8 wherein R8 is as defined above and R4 together with R5 is a single bond; or (b) R5 together with R6 is a keto group and R4 is hydrogen.
    可用作抗病毒剂的化合物由下式定义: 及其酸加成盐,最好是药学上可接受的酸加成盐,其中 R1 是氢或-C(O)R7,其中 R7 是氢、1 至 19 个碳原子的烷基、1 至 8 个碳原子的羟烷基、2 至 9 个碳原子的烷氧基烷基、2 至 19 个碳原子的烯基、苯基、1-金刚烷基、2-羧乙基或羧甲基及其药学上可接受的碱金属盐; R2 是-C(O)R7,其中 R7 如上定义; R3 是氢、卤代、硫代、一至六个碳原子的低级烷硫基、叠氮、NR9R10(其中 R9 和 R10 独立地是氢或一至六个碳原子的低级烷基)或-NHC(O)R8(其中 R8 是氢、一至十九个碳原子的烷基或 1-金刚烷基);以及 (a) R6 为氢、卤素、一至六个碳原子的低级烷氧基、叠氮、硫代、一至六个碳原子的低级烷硫基、-NR9R10(其中 R9 和 R10 如上所定义)或-NHC(O)R8(其中 R8 如上所定义),且 R4 与 R5 一起为单键;或 (b) R5 与 R6 同为酮基,R4 为氢。
  • Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-di-0-substituted 1,3 dihydroxy-2-propoxymethyl) purines as antiviral agents
    申请人:SYNTEX (U.S.A.) INC.
    公开号:EP0105135A1
    公开(公告)日:1984-04-11
    Compounds useful as antiviral agents are defined by the following formula: wherein R1 is hydrogen, -C(Y)OR7 or -C(O)NHR7 wherein R7 is alkyl of one to twelve carbon atoms, alkenyl of two to twelve carbon atoms, cyclopentyl, cyclohexyl, phenyl or benzyl; R2 is -C(Y)OR7 or -C(O)NHR7 wherein R7 is as defined above; Y is oxygen or sulfur; R3 is hydrogen, halo, thio, lower alkylthio of one to six carbon atoms, azido, NR9R10 wherein R9 and R10 are independently hydrogen or lower alkyl of one to six carbon atoms or -NHC(O)R8 wherein R8 is hydrogen, alkyl of one to nineteen carbon atoms or 1-adamantyl; and (a) R6 is hydrogen, halo, lower alkoxy of one to six carbon atoms, azido, thio, lower alkylthio of one to six carbon atoms, -NR9R10 wherein R9 and R10 are as defined above or -NHC(O)R8 wherein R8 is as defined above and R4 together with R5 is a bond; or (b) R5 together with R6 is a keto group and R4 is hydrogen.
    可用作抗病毒剂的化合物按下式定义: 其中 R1是氢、-C(Y)OR7或-C(O)NHR7,其中R7是一至十二个碳原子的烷基、二至十二个碳原子的烯基、环戊基、环己基、苯基或苄基; R2 是-C(Y)OR7 或-C(O)NHR7,其中 R7 如上定义; Y 是氧或硫; R3 是氢、卤素、硫代、一至六个碳原子的低级烷硫基、叠氮、NR9R10(其中 R9 和 R10 独立地是氢或一至六个碳原子的低级烷基)或-NHC(O)R8(其中 R8 是氢、一至十九个碳原子的烷基或 1-金刚烷基);以及 (a) R6 是氢、卤素、1 至 6 个碳原子的低级烷氧基、叠氮、硫代、1 至 6 个碳原子的低级烷硫基、-NR9R10(其中 R9 和 R10 如上所定义)或-NHC(O)R8(其中 R8 如上所定义)且 R4 与 R5 一起是键;或 (b) R5 与 R6 同为酮基,R4 为氢。
  • Antiviral purine derivatives
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:EP0108285A2
    公开(公告)日:1984-05-16
    Compounds of the general formula (wherein X is sulphur or oxygen or a chemical bond; R' is halogen, amino or azido; R2 is hydrogen, hydroxy, alkyl or hydroxyalkyl; R3 is hydrogen or alkyl; R4 is hydroxy, hydroxyalkyl, benzyloxy, phosphate or carboxypropionyloxy; R5 is hydrogen, alkyl or hydroxyalkyl) and salts and esters thereof, have been found to have valuable antiviral activity particularly against herpes viruses. Methods for the preparation of the above compounds are described as well as pharmaceutical formulations containing such compounds.
    通式如下的化合物 (其中 X 是硫或氧或化学键;R'是卤素、氨基或叠氮;R2 是氢、羟基、烷基或羟烷基;R3 是氢或烷基;R4 是羟基、羟烷基、苄氧基、磷酸或羧丙酰氧基;R5 是氢、烷基或羟烷基)的化合物及其盐和酯,特别是对疱疹病毒具有重要的抗病毒活性。本文介绍了上述化合物的制备方法以及含有此类化合物的药物制剂。
查看更多